Radius Health, Inc. (RDUS)

NASDAQ: RDUS · IEX Real-Time Price · USD
5.31
-0.58 (-9.85%)
May 18, 2022 12:36 PM EDT - Market open
Market Cap252.60M
Revenue (ttm)216.87M
Net Income (ttm)-72.70M
Shares Out47.57M
EPS (ttm)-1.49
PE Ration/a
Forward PE8.64
Dividendn/a
Ex-Dividend Daten/a
Volume483,903
Open5.61
Previous Close5.89
Day's Range5.30 - 5.63
52-Week Range5.27 - 23.00
Beta0.93
AnalystsSell
Price Target8.84 (+66.5%)
Earnings DateMay 5, 2022

About RDUS

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901)...

IndustryBiotechnology
IPO DateJun 6, 2014
CEOG. Kelly Martin
Employees293
Stock ExchangeNASDAQ
Ticker SymbolRDUS
Full Company Profile

Financial Performance

In 2021, Radius Health's revenue was $229.97 million, a decrease of -3.63% compared to the previous year's $238.65 million. Losses were -$70.18 million, -35.74% less than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for RDUS stock is "Sell." The 12-month stock price forecast is 8.84, which is an increase of 66.48% from the latest price.

Price Target
$8.84
(66.48% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline

Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.

1 week ago - Zacks Investment Research

Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates

Radius Health (RDUS) delivered earnings and revenue surprises of -85.71% and 16.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Radius Health, Inc. First Quarter 2022 Results

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the first quarter ended March 31, 2022. The Company also...

1 week ago - GlobeNewsWire

Radius Health (RDUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May...

BOSTON, April 25, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday, May 5...

3 weeks ago - GlobeNewsWire

Radius Health Announces Leadership Appointments

BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately.

2 months ago - GlobeNewsWire

Radius Health Provides Business Update on Bone Health

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on business development and intellectual property progress in its Bone Health...

2 months ago - GlobeNewsWire

Wells Fargo Equity Research to Host Fireside Chat with Radius CEO

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that Kelly Martin, CEO, has accepted an invitation to participate in a virtual f...

2 months ago - GlobeNewsWire

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estim...

2 months ago - Zacks Investment Research

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.

2 months ago - Zacks Investment Research

Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates

Radius Health (RDUS) delivered earnings and revenue surprises of 5.71% and 3.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Radius Health, Inc. Fourth Quarter & Full Year 2021 Results

BOSTON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the fourth quarter and full year ended December 31, 202...

2 months ago - GlobeNewsWire

Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast o...

BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. ...

3 months ago - GlobeNewsWire

New Strong Sell Stocks for January 26th

ISRG, KOP, LPL, NOA, and RDUS have been added to the Zacks Rank #5 (Strong Sell) List on January 26, 2021.

Other symbols:ISRGKOPLPLNOA
3 months ago - Zacks Investment Research

Radius Health Completes Business Adjustment

BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), has completed an adjustment of its business.

4 months ago - GlobeNewsWire

FDA Approves Update On Radius Health's Tymlos label

The FDA has approved updates to Radius Health Inc's (NASDAQ: RDUS) Tymlos label, including removing the boxed warning regarding the risk of osteosarcoma, a type of cancer. The removal of the boxed warni...

4 months ago - Benzinga

Radius Announces Update on TYMLOS® (abaloparatide) Label

BOSTON, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYML...

4 months ago - GlobeNewsWire

Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS

Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.

5 months ago - Zacks Investment Research

Why Radius Health Stock Is Getting Pummeled Today

A closer look at the clinical trial results that drove the stock up in October was a little disappointing.

5 months ago - The Motley Fool

Radius Health Reveals Detailed Elacestrant Data From Late-Stage Breast Cancer Trial

The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have provided details on the elacestrant data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. As previously a...

5 months ago - Benzinga

Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

FLORENCE, Italy and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) provided details on the el...

5 months ago - GlobeNewsWire

Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women ...

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (...

5 months ago - GlobeNewsWire

Radius Health to Host Conference Call Today, Wednesday, December 8, 2021

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to c...

5 months ago - GlobeNewsWire

Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines

Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.

6 months ago - Zacks Investment Research